Education
About Us
Working with TipRanks
Follow Us
Profusa, Inc. (PFSA)
:PFSA
PFSA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $13.25
Previous CloseN/A
VolumeN/A
Average Volume (3M)10.85M
Market Cap
$13.82M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.16
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding40,859,306
10 Day Avg. Volume1,656,901
30 Day Avg. Volume10,846,067
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Profusa News
PFSA FAQ
What was Profusa, Inc.’s price range in the past 12 months?
Profusa, Inc. lowest stock price was $0.27 and its highest was $13.25 in the past 12 months.
What is Profusa, Inc.’s market cap?
Profusa, Inc.’s market cap is $13.82M.
When is Profusa, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Profusa, Inc.’s earnings last quarter?
Currently, no data Available
Is Profusa, Inc. overvalued?
According to Wall Street analysts Profusa, Inc.’s price is currently Overvalued.
Does Profusa, Inc. pay dividends?
Profusa, Inc. does not currently pay dividends.
What is Profusa, Inc.’s EPS estimate?
Profusa, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Profusa, Inc. have?
Profusa, Inc. has 40,859,306 shares outstanding.
What happened to Profusa, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Profusa, Inc.?
Currently, no hedge funds are holding shares in PFSA
Company Description
Profusa, Inc.
A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia
Technical Analysis
Silexion Therapeutics
―
NeueHealth Inc
―
CERo Therapeutics Holdings
―
New Era Energy & Digital
―
Beta Bionics, Inc.
―